Наша цель — спасти Ваше зрение
 
Choose Language
  • French
  • Deutsch
  • Italian
  • Russian
  • Japanese
  • Espanol
  • English
Connect and Share
Цвет: 
    Color Color Color Color
Размер шрифта: 
    Size Size Size Size
    Join

Главное меню

Перейти к основному содержимому
Перейти к дополнительному содержимому
  • СВЕДЕНИЯ
  • ЛЕЧЕНИЕ
  • Источники
  • КОНТАКТЫ
  • ГЛАВНАЯ
  • Дар
You need Flash player 8+ and JavaScript enabled to view this video.
Если Вы отмечаете искажение или расплывчатость изображения, видите серые пятна, не мешкайте.

Срочно обратитесь к врачу.

Возможно, еще не поздно все
исправить.

УЗНАТЬ БОЛЬШЕ о влажной
(неоваскулярной) ВМД
Ранняя диагностика ВМД крайне важна
для сохранения зрения.

Получите правильное лечение влажной ВМД:
антиангиогенная терапия.


ЛЕЧЕНИЕ влажной ВМД
You need Flash player 8+ and JavaScript enabled to view this video.
You need Flash player 8+ and JavaScript enabled to view this video.
News
Archive >


FDA approves faricimab for treatment of wet AMD and DME
Faricimab will be the first and only FDA-approved medicine targeting two distinct pathways, Ang-2 and VEGF-A, involved in retinal diseases and ... Read More >

(English) Novartis Provides Update on Use and Safety of Beovu in Patients With Wet AMD
(English) After the American Society of Retinal Specialists (ASRS) shared a note with its membership warning of vision-threatening cases of occlusive retinal vasculitis of wet AMD drug Beovu, Novartis... Read More >

(English) Beovu Approved for Wet AMD in European Union
(English) Following the Euopean Medicines Agency (EMA) human medicine’s committee recommendation in December, Beovu (brolucizumab) received formal approval by the European Commission … Sour... Read More >

(English) AMD Incidence to Rise by 75% and Affect 77 million Europeans by 2050
(English) In latest calculations, researchers pooled data from 22 prevalence studies involving 55,323 people, aged, on average, between 60 and 81, and from four incidence studies across Europe … ... Read More >

(English) Opthea OPT-302 Combo Outshines Lucentis Alone
(English) At EURETINA 2019 Congress, the Australia based company Ophthea reported data that OPT-302 reduced areas of neovascularization by 38% more and decreased scarring by 39% more, compared to Luce... Read More >

(English) Positive phase 2 trial results of anti-VEGF abicipar pegol for treating wet AMD
(English) Analysis of data from a Phase 2 study of abicipar pegol (Anti-VEGF DARPin®) in neovascular, or “wet,” age-related macular degeneration (AMD) showed positive results, leading to the deci... Read More >

           
Призыв к действию
Узнайте насколько важно раннее выявление заболевания врачом-офтальмологом для сохранения Вашего зрения. Узнайте, какие виды терапии подойдут именно Вам. Получите доступ к нужным ресурсам. Вместе мы повысим степень информированности.
Recent Activity
September 5, 2017
The Angiogenesis Foundation

The Angiogenesis Foundation is launching a useful educational resource on geographic atrophy, the advanced atrophic form of AMD.

The Angiogenesis Foundation will be launching a Geographic Atrophy (GA) Multimedia Educational Toolkit this week at Euretina!

http://www.prnewswire.co.uk/news-releases/the-angiogenesis-foundation-launches-geographic-atrophy-ga-multimedia-educational-toolkit-at-euretina-642658903.html

View on facebook
  • • Загрузка брошюры для пациентов
  • Глоссарий
  • Контакты
  • Политика конфиденциальности
  • Заявление-отказ от ответственности
  • Поддержка сайта
The Angiogenesis Foundation - One Broadway, 14th fl, Cambridge, MA 02142, (617) 401-2779 amd@angio.org
This website is certified by Health On the Net Foundation. Click to verify.
(English) This site has been determined by HON in Geneva, Switzerland to comply with standards for trustworthy health information.